CETUXIMAB and DYSPNOEA

Overview

DYSPNOEA is the #6 most commonly reported adverse reaction for CETUXIMAB, manufactured by ImClone LLC. There are 1,357 FDA adverse event reports linking CETUXIMAB to DYSPNOEA. This represents approximately 2.6% of all 51,547 adverse event reports for this drug.

Patients taking CETUXIMAB who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

DYSPNOEA is a less commonly reported adverse event for CETUXIMAB, but still significant enough to appear in the safety profile.

Other Side Effects of CETUXIMAB

In addition to dyspnoea, the following adverse reactions have been reported for CETUXIMAB:

• RASH — 2,235 reports
• DIARRHOEA — 1,987 reports
• OFF LABEL USE — 1,798 reports
• NAUSEA — 1,617 reports
• VOMITING — 1,372 reports
• NEUTROPENIA — 1,202 reports
• PYREXIA — 1,114 reports
• DEHYDRATION — 1,098 reports
• INFUSION RELATED REACTION — 1,083 reports
• MALIGNANT NEOPLASM PROGRESSION — 1,058 reports

Other Drugs Associated with DYSPNOEA

The following drugs have also been linked to dyspnoea in FDA adverse event reports:

Does CETUXIMAB cause DYSPNOEA?

DYSPNOEA has been reported as an adverse event in 1,357 FDA reports for CETUXIMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is DYSPNOEA with CETUXIMAB?

DYSPNOEA accounts for approximately 2.6% of all adverse event reports for CETUXIMAB, making it a notable side effect.

What should I do if I experience DYSPNOEA while taking CETUXIMAB?

If you experience dyspnoea while taking CETUXIMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages